Thursday, February 14, 2013
OSAKA (Nikkei)--The first-ever clinical trial of induced pluripotent stem cells, or iPS cells, may begin as early as the upcoming fiscal year as Japanese researchers look to use the Nobel Prize-winning discovery to treat an eye disease.read full article...
This article is available to Nikkei.com subscribers only.
Please log in to read the entire article, or learn about Nikkei.com subscription offers below.
Nikkei.com is the English-language online flagship of Japan?s leading business news publisher, Nikkei Inc.
Harnessing the editorial power of Nikkei Inc., Nikkei.com offers unsurpassed access to the latest business intelligence and market data from Japan.
No matter what your business is in Japan, Nikkei.com is an indispensable resource.
Join now to get round-the-clock business new, market data and stock quotes from Japan, fresh from the newsroom to your desktop!
Subscription Fees :
9,450 yen for 6 months or 16,800 yen for one year(*We will deduct 5% consumption tax on prices above if you reside outside of Japan) Learn more about Nikkei.com and our subscription options.
Source: http://e.nikkei.com/e/app/fr/gateway/rss_news.aspx?URL=/e/ac/tnks/Nni20130213D1302A13.htm
doug hutchison larry brown thomas kinkade pat summit brewers matt cain adastra
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.